Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
about
Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell linesSLE - Rituximab in lupusThe role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literatureEffects of rituximab in two patients with dysferlin-deficient muscular dystrophy.A human immunoglobulin G1 antibody originating from an in vitro-selected Fab phage antibody binds avidly to tumor-associated MUC1 and is efficiently internalized.Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development.Determination of primary structure and microheterogeneity of a beta-amyloid plaque-specific antibody using high-performance LC-tandem mass spectrometry.Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study.Cancer targeted therapeutics: From molecules to drug delivery vehicles.Current and novel therapeutics in the treatment of systemic lupus erythematosusB-lymphocyte-mediated delayed cognitive impairment following stroke.Update on rituximab.Recombinant chimeric antibody hCAb as a novel anti-human colorectal carcinoma agentPrior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantationRituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid homeostasis.CAR-T Cell Therapies From the Transfusion Medicine PerspectiveBiological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.An open-label trial of rituximab therapy in pulmonary alveolar proteinosis.Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy.Self-assembled antibody multimers through peptide nucleic acid conjugation.Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia.Fixed Dosing of Monoclonal Antibodies in Oncology.Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.Pentostatin, Cyclophosphamide and Rituximab (PCR) Regimen.A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs).Clinical responses to rituximab in a case of neuroblastoma with refractory opsoclonus myoclonus ataxia syndrome.CD20-targeted measles virus shows high oncolytic specificity in clinical samples from lymphoma patients independent of prior rituximab therapy.Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical stem cell transplantation.Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells.Rituximab-induced interleukin-15 reduction associated with clinical improvement in rheumatoid arthritis.A novel glycosylated anti-CD20 monoclonal antibody from transgenic cattle
P2860
Q24650717-14C8AF93-3785-4F98-A2F6-1AD3B59EA82DQ24804739-9AB7DDBD-63AA-4A2E-9CDE-BE8B4B09A842Q28067526-4A716D1B-B2C4-4B99-9BDC-11AF907B627CQ30985481-DD7F7534-0C86-4A61-92DA-1C961BE9183FQ31051574-AAD88E07-2A08-4016-815D-65D51D267C87Q33380175-14DF8256-5E24-4CD9-B644-F8A325036944Q33743933-FC7C2601-9291-4236-8EA3-CB658B0EE7C5Q33885872-5A64A986-2E8E-42E0-A338-E072A1AD3BF0Q33887986-FD678832-88D1-4304-BB78-F3553383C2A3Q34648851-130C36C9-7E6B-4EB9-9F17-90590360F0A2Q35044819-29396341-F483-4CA7-9A6B-9217E3769499Q35579499-24441188-0D18-451D-925A-4C3938C37B2BQ35586920-B0A7E62C-2E47-49DE-AE88-DEB6D736A645Q35970489-A36ED60A-9C99-4413-A58E-CF3D5ED20E70Q36204781-2F3E0F41-8369-4BAF-9077-C9D58D59E009Q37022738-A97A7E18-5D47-46F1-A7DE-2C44AB5476B5Q37290665-50C883EC-1CCD-47B1-8C33-088459BFBF21Q37418292-C1B2CE78-907C-4C83-BE3D-E96D5230A6B3Q37552019-ACB4B5E6-2D00-40F2-AC0B-A750BE875614Q37633102-5FD980A3-9305-4374-B1F0-782DB93D9A46Q38100787-D797EC02-A335-4513-AAB6-954817230DCDQ38654371-A4828533-817E-4954-A2FD-A179E3A3B0CEQ38795442-BF1312A0-3CD8-4B1D-AC4B-9A9BA8A5541CQ39037182-FAD238D4-B062-4F37-A3AB-E63EA4D8B44CQ41475288-E77459DB-963A-4B24-B1BA-ED9065F76648Q41620536-3A2C33BC-A8D9-4D56-980B-01E89CC40FE0Q41880131-A40718D5-1991-42A1-852D-A89D10E170C8Q41899939-BEFE3211-DBFA-4748-B556-DF8CC0473526Q42077750-509042E1-4DC8-4CC3-8969-0CFCCE221BABQ50872769-93DCD727-9E40-4223-99AB-88113ABD81DCQ58765419-158853F2-CBA5-4BD4-97DD-2B48D168D7F3
P2860
Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Overview of the clinical devel ...... for the treatment of lymphoma.
@ast
Overview of the clinical devel ...... for the treatment of lymphoma.
@en
type
label
Overview of the clinical devel ...... for the treatment of lymphoma.
@ast
Overview of the clinical devel ...... for the treatment of lymphoma.
@en
prefLabel
Overview of the clinical devel ...... for the treatment of lymphoma.
@ast
Overview of the clinical devel ...... for the treatment of lymphoma.
@en
P2093
P1433
P1476
Overview of the clinical devel ...... for the treatment of lymphoma.
@en
P2093
Dallaire BK
Grillo-López AJ
P433
5 Suppl 14
P577
1999-10-01T00:00:00Z